ASRT241220P4000
- 2.61
- 0.000.00%
Assertio Newsroom
Lake Street Sticks to Its Buy Rating for Assertio Therapeutics (ASRT)
Assertio Holdings Analyst Ratings
H.C. Wainwright Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $4
Assertio Therapeutics: Strong Buy Rating Backed by Robust Margins and Strategic Revenue Growth
US Manufacturing Index Rises To 43, Highest Since 2020
Maxim Group Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
US$3.15: That's What Analysts Think Assertio Holdings, Inc. (NASDAQ:ASRT) Is Worth After Its Latest Results
Assertio Holdings Third Quarter 2024 Earnings: Beats Expectations
A. G. P. Maintains Assertio(ASRT.US) With Buy Rating, Cuts Target Price to $2.15
Assertio | 10-Q: Q3 2024 Earnings Report
Assertio Therapeutics Reports Strong Q3 and Board Changes
Assertio | 8-K: Assertio Reports Third Quarter 2024 Financial Results
Q3 2024 Assertio Holdings Inc Earnings Call
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Assertio Therapeutics (ASRT) Receives a Buy From Lake Street
Assertio Therapeutics' Q3 2024 Earnings Overview
Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript Summary
Assertio Stock Gains Amid Clash With Activist Investor, Q3 Earnings
Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates
Earnings Snapshot: Assertio Holdings Tops Q3 Expectations; Rolvedon Sales Remain Stable